New therapeutic approaches to peptic ulcer disease: The role of Helicobacter pylori

Seymour I. Schlager*, Stephen B. Hanauer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


One of the most common bacterial infections of humans involves Helicobacter pylori, a spiral, gram-negative bacterium that is now thought to be a dominant factor in the development of peptic ulcer disease and may be significant in causing certain forms of gastric cancer. Almost 100% of patients with duodenal ulcer and 70 to 90% affected with gastric ulcer are infected with H. pylori. In order to achieve cure H. pylori-induced ulcer disease, it is necessary to eradicate the bacterial infection. Mere suppression or clearance of infection without eradication is associated with a >80% recurrence of the ulcer. The epidemiology, microbiology, and pathogenesis of H. pylori infections are reviewed. Diagnostic methods and optimal treatment strategies for H. pylori infections are examined the most current diagnostic and treatment algorithms for peptic ulcer disease are discussed critically, and future directions for drug development aimed at eradication of H. pylori infection are considered.

Original languageEnglish (US)
Pages (from-to)586-596
Number of pages11
JournalAmerican journal of therapeutics
Issue number8
StatePublished - Aug 1996


  • Helicobacter pylori
  • antibiotics
  • diagnosis
  • epidemiology
  • gastric cancer
  • microbiology
  • peptic ulcer disease
  • protein pump inhibitors
  • treatment algorithms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'New therapeutic approaches to peptic ulcer disease: The role of Helicobacter pylori'. Together they form a unique fingerprint.

Cite this